All In Biotech

Drug Trial Radar · NCT04492020

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome

Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

518

Actual

Start

Aug 21, 2020

Primary completion

Apr 19, 2022

Study completion Apr 19, 2022

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome

Conditions

  • Migraine

Interventions

  • Ubrogepant 100 mgDrug

    For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours

  • PlaceboDrug

    For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-doseTime frame: 24 hours after taking double-blind study intervention during the prodrome

Locations

73 sites in 1 country. Site status is shown where the registry gives one.

  • Achieve Clinical Research, LLC /ID# 237098

    Birmingham, Alabama

  • Barrow Neuro Institute /ID# 236775

    Phoenix, Arizona

  • Arkansas Clinical Research /ID# 238032

    Little Rock, Arkansas

  • California Headache and Balance Center /ID# 236247

    Fresno, California

  • Sun Valley Research Center /ID# 236561

    Imperial, California

  • Wr-Pri Llc /Id# 236007

    Los Alamitos, California

  • Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 237691

    Newport Beach, California

  • Excell Research, Inc /ID# 237721

    Oceanside, California

  • George J. Rederich M.D. Inc. /ID# 235769

    Torrance, California

  • Diablo Clinical Research /ID# 237570

    Walnut Creek, California

  • Colorado Springs Neurological Associates (CSNA) /ID# 236556

    Colorado Springs, Colorado

  • Advanced Neurosciences Research, LLC /ID# 237426

    Fort Collins, Colorado

  • CNS Healthcare - Jacksonville /ID# 238245

    Jacksonville, Florida

  • Health Awareness, Inc - Jupiter /ID# 236226

    Jupiter, Florida

  • Suncoast Clinical Research /ID# 236934

    New Port Richey, Florida

  • Sensible Healthcare /ID# 238090

    Ocoee, Florida

  • Clinical Neuroscience Solutions, Inc /ID# 236608

    Orlando, Florida

  • Accel Research Sites - St Petersburg Clinical Research Unit /ID# 237163

    St. Petersburg, Florida

  • University of South Florida /ID# 234387

    Tampa, Florida

  • ForCare Clinical Research /ID# 237092

    Tampa, Florida

  • Premiere Research Institute - Palm Beach /ID# 238193

    West Palm Beach, Florida

  • NeuroTrials Research Inc. /ID# 237365

    Atlanta, Georgia

  • iResearch Atlanta, LLC /ID# 237390

    Decatur, Georgia

  • Meridian Clinical Research (Neurology) - Savannah /ID# 234371

    Savannah, Georgia

  • Clinical Research Atlanta - Headlands LLC /ID# 234438

    Stockbridge, Georgia

  • Northwest Clinical Trials /ID# 234968

    Boise, Idaho

  • Deaconess Clinic Downtown /ID# 236959

    Evansville, Indiana

  • PMG Research of McFarland /ID# 238271

    Ames, Iowa

  • Collective Medical Research /ID# 236402

    Overland Park, Kansas

  • Kansas Institute of Research /ID# 236738

    Overland Park, Kansas

  • Boston Clinical Trials /ID# 236559

    Boston, Massachusetts

  • Michigan Headache & Neurological Institute (MHNI) /ID# 236565

    Ann Arbor, Michigan

  • Minneapolis Clinic of Neurology - Golden Valley /ID# 238162

    Golden Valley, Minnesota

  • Clinical Research Institute, Inc /ID# 238301

    Minneapolis, Minnesota

  • StudyMetrix Research /ID# 236457

    City of Saint Peters, Missouri

  • Clinvest Research LLC /ID# 237908

    Springfield, Missouri

  • Princeton Center for Clinical Research /ID# 235734

    Skillman, New Jersey

  • Bio Behavioral Health, Inc /ID# 238212

    Toms River, New Jersey

  • Dent Neurosciences Research Center, Inc. /ID# 237039

    Amherst, New York

  • Central New York Clinical Research /ID# 235694

    Manlius, New York

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.